Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
---- Lubberding AF, Veedfald S, Achter JS, Nissen SD, Soattin L, Sorrentino A, Vega ET, Linz B, Eggertsen CHE, Mulvey J, Torng S, Larsen SA, Nissen A, Petersen LG, Bilir SE, Bentzen BH, Rosenkilde MM, Hartmann B, Liller TNB, Qazi S, Mller CH, Tfelt-Hansen J, Sattler SM, Jespersen T, Holst JJ, Lundby A
Compared with the phase III trial data of GLP-1 related dual agonist drugs that have been published, the incidence of gastrointestinal adverse events and treatment discontinuation rate are lower
When staying with tirzepatide makes more sense Tirzepatide remains the better choice in several scenarios
As of 2024, Wegovy also has an additional approval: to reduce the risk of major cardiovascular events (like heart attack and stroke) in adults with obesity or overweight
